HIV Infection clinical trials
Showing 51–80 of 80 active trials naming this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
- Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy
- Accelerated ART Initiation for PWHIV Who Are Out of Care
- Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
- SCOPE Analytic Treatment Interruption Protocol
- Stress and Pain in People Living With HIV
- Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
- IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
- Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Topical Curcumin for HPV Related Cervical Disease
- CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
- A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
- Nirogacestat in Patients With Kaposi Sarcoma
- A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations
- Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
- C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States
- New York City Observational Study of Mpox Immunity
- HPV Self-sampling to Improve Access to Cervical Cancer Screening for Persons With HIV and/or Underserved Individuals
- Analytic Treatment Interruption (ATI) to Assess HIV Cure
- Analysis of HIV-1 Replication During Antiretroviral Therapy
- Clinic-Community Bridge to Improve Health Outcomes for Abused Women Living With HIV/AIDS
- Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART
- Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma
- Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home
- Addressing Psychosocial Comorbidities in HIV Treatment and Prevention 2b
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
- Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
- Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
- Tfh Dysfunction in HIV and Aging
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.